arrow
C

Carlos Gomez-Roca

yonsei university health system
H指数:41
被引数:6,667

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti- PD-1 monoclonal antibody in patients with advanced solid tumours

I期剂量递增研究评估OSE-279(一种抗PD-1单克隆抗体)在晚期实体瘤患者中的安全性、药代动力学和药效动力学

2026-04-090
PRE
Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study

仑伐替尼联合帕博利珠单抗用于既往治疗过的晚期胃癌、胆道癌或胰腺癌患者:LEAP-005 II期研究的结果

2026-03-012
PRE
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial

帕博利珠单抗和伏立诺他联合治疗复发性/转移性鳞状细胞癌的疗效:一项II期篮式试验

2025-06-300
OAAI
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)

ESMO临床获益程度量表2.0版(ESMO-MCBS v2.0)

2025-05-220
PRE
Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1+antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics

通过空间转录组学和血浆蛋白质组学鉴定与胃癌anti-PD-1/PD-L1抗血管生成相关的微环境特征

2024-09-131
OAAI
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
2024-04-173
OAAI
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment

ATR抑制剂ceralasertib通过调节肿瘤微环境来增强癌症检查点免疫治疗

2024-02-248
OAAI
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers
2024-01-2410
PRE
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma
2023-12-016
OAAI
OSE279, a PD-1 blocking monoclonal antibody, as future backbone of a bifunctional checkpoint inhibitor platform: Preclinical characterization and early clinical results of a First-In-Human (FIH) study in subjects with advanced malignancies
2023-12-010
PRE
Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
2023-10-010
OA
Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
2023-10-011
PRE
Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma of the penis: Subgroup analysis of the PEVOsq basket trial
2023-10-010
OA